Oncolytic virotherapy in the treatment of melanoma

Bookmark and Share
Published: 26 Sep 2016
Views: 1814
Dr Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

Dr Andtbacka meets with ecancertv at WCCS 2016 to discuss the use of oncolytic virotherapy (OV) in the treatment of melanoma.

He discusses the OPTiM trials of T-VEC, a genetically modified herpes virus, including identifying which patients have the most durable response, and looks forward to potential combinations for T-VEC and other OVs.

For more on oncolytic virotherapy, you can read a brief history here.

ecancer's filming at WCCS 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.